Angiochem Receives Innovation Award From the National Brain Tumor Society for
Advancing the Development of Novel Brain Cancer Treatments
EPiC Technology Platform Creates Anti-Cancer Compounds Crossing the
Blood-Brain-Barrier Through LRP-1 Targeting
MONTREAL, CANADA, AND WATERTOWN, MASSACHUSETTS, Feb 15, 2011 (MARKETWIRE via
COMTEX) -- Angiochem, Inc., a clinical stage biotechnology company, and the
National Brain Tumor Society (NBTS), a leading U.S. non-profit organization in
the brain tumor community, today announced that Angiochem has been presented with
the Innovation Recognition Award from the National Brain Tumor Society for its
progress in developing novel treatments for brain tumors that are capable of
crossing the blood-brain barrier. The NBTS Innovation Recognition Award
acknowledges catalytic research projects that will significantly move forward the
field of brain tumor research.
Angiochem utilizes its proprietary platform for Engineered Peptide Compounds
(EPiC) to discover and develop drugs that cross the blood-brain barrier through
Low-Density Lipoprotein Receptor Related Protein-1 (LRP-1) targeting. Angiochem's
most advanced product candidate, GRN1005 (formerly ANG1005), was recently
licensed to Geron Corporation for the treatment of patients with primary and
metastatic brain tumors.
"The blood-brain barrier is one of several factors that make brain tumors
difficult to treat," said N. Paul TonThat, Executive Director of The National
Brain Tumor Society. "For the hundreds of thousands of people in the U.S. who are
living with or will be diagnosed with primary or metastatic brain tumors, the
work being done by AngioChem represents a promising approach to overcoming one of
those challenges by enabling drugs to cross the blood-brain barrier."
"We are honored to be acknowledged by the NBTS with this award, as we continue
our mission of developing novel drugs to help patients for diseases with
significant unmet needs, such as brain cancer" commented Jean-Paul Castaigne, MD,
President and CEO of Angiochem. "Our EPiC platform technology has demonstrated
the ability to penetrate brain tissue and, more importantly, brain tumors with
compelling preliminary evidence of anti-tumor activity."
About the National Brain Tumor Society
National Brain Tumor Society is fiercely committed to improving the quality of
life of all those affected by brain tumors. NBTS is dedicated to help: empower
individuals with comprehensive information, online programs, caring support, and
direct connections to others going through the same challenges; fund
transformative research to lead more rapidly to new therapies for adult and
pediatric brain tumors, and ultimately to cures; advocate for brain tumor
patients, families, caregivers, healthcare professionals, and researchers.
About Angiochem
Angiochem is a clinical-stage biotechnology company discovering and developing
new breakthrough drugs that are leveraging the LRP-1 mediated pathway to cross
the blood-brain barrier (BBB) to treat brain diseases. These new Engineered
Peptide Compounds (EPiC) have the potential to address significant medical needs,
many of which cannot be effectively addressed due to the fundamental
physiological challenge the blood-brain barrier presents for therapeutic
intervention. Angiochem is developing a deep and broad product pipeline,
including small molecules and biologics, for the potential treatment of a wide
range of CNS diseases, including brain cancer, neurodegenerative and metabolic
diseases, pain, and many others. Founded in 2003, Angiochem maintains
headquarters in Montreal, Canada. For additional information about the Company,
please visit angiochem.com.
Contacts:
Angiochem Contact:
The Yates Network
Gina Nugent
617-460-3579
National Brain Tumor Society Contact:
Lisa McEvoy
617-924-9997 x1410 |
